1
|
Imir OB, Kaminsky AZ, Zuo QY, Liu YJ, Singh R, Spinella MJ, Irudayaraj J, Hu WY, Prins GS, Madak Erdogan Z. Per- and Polyfluoroalkyl Substance Exposure Combined with High-Fat Diet Supports Prostate Cancer Progression. Nutrients 2021; 13:3902. [PMID: 34836157 PMCID: PMC8623692 DOI: 10.3390/nu13113902] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2021] [Revised: 10/27/2021] [Accepted: 10/27/2021] [Indexed: 01/25/2023] Open
Abstract
Per- and polyfluoroalkyl substances (PFAS) are synthetic chemicals utilized in various industrial settings and include products such as flame retardants, artificial film-forming foams, cosmetics, and non-stick cookware, among others. Epidemiological studies suggest a link between increased blood PFAS levels and prostate cancer incidence, but the mechanism through which PFAS impact cancer development is unclear. To investigate the link between PFAS and prostate cancer, we evaluated the impact of metabolic alterations resulting from a high-fat diet combined with PFAS exposure on prostate tumor progression. We evaluated in vivo prostate cancer xenograft models exposed to perfluorooctane sulfonate (PFOS), a type of PFAS compound, and different diets to study the effects of PFAS on prostate cancer progression and metabolic activity. Metabolomics and transcriptomics were used to understand the metabolic landscape shifts upon PFAS exposure. We evaluated metabolic changes in benign or tumor cells that lead to epigenomic reprogramming and altered signaling, which ultimately increase tumorigenic risk and tumor aggressiveness. Our studies are the first in the field to provide new and clinically relevant insights regarding novel metabolic and epigenetic states as well as to support the future development of effective preventative and therapeutic strategies for PFAS-induced prostate cancers. Our findings enhance understanding of how PFAS synergize with high-fat diets to contribute to prostate cancer development and establish an important basis to mitigate PFAS exposure.
Collapse
Affiliation(s)
- Ozan Berk Imir
- Division of Nutritional Sciences, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA;
| | - Alanna Zoe Kaminsky
- Department of Food Science and Human Nutrition, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA; (A.Z.K.); (Q.-Y.Z.); (Y.-J.L.)
| | - Qian-Ying Zuo
- Department of Food Science and Human Nutrition, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA; (A.Z.K.); (Q.-Y.Z.); (Y.-J.L.)
| | - Yu-Jeh Liu
- Department of Food Science and Human Nutrition, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA; (A.Z.K.); (Q.-Y.Z.); (Y.-J.L.)
| | - Ratnakar Singh
- Comparative Biosciences, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA; (R.S.); (M.J.S.)
| | - Michael J. Spinella
- Comparative Biosciences, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA; (R.S.); (M.J.S.)
- Cancer Center at Illinois, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA;
- Beckman Institute of Technology, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA
| | - Joseph Irudayaraj
- Cancer Center at Illinois, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA;
- Institute of Genomic Biology, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA
- Beckman Institute of Technology, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA
- Department of Bioengineering, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA
- Departments of Urology, Pathology and Physiology, College of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA; (W.-Y.H.); (G.S.P.)
| | - Wen-Yang Hu
- Departments of Urology, Pathology and Physiology, College of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA; (W.-Y.H.); (G.S.P.)
- Chicago Center for Health and Environment, University of Illinois at Chicago, Chicago, IL 60612, USA
| | - Gail S. Prins
- Departments of Urology, Pathology and Physiology, College of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA; (W.-Y.H.); (G.S.P.)
- Chicago Center for Health and Environment, University of Illinois at Chicago, Chicago, IL 60612, USA
| | - Zeynep Madak Erdogan
- Division of Nutritional Sciences, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA;
- Department of Food Science and Human Nutrition, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA; (A.Z.K.); (Q.-Y.Z.); (Y.-J.L.)
- Cancer Center at Illinois, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA;
- Institute of Genomic Biology, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA
- Beckman Institute of Technology, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA
| |
Collapse
|
2
|
Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance. Cancers (Basel) 2019; 11:cancers11040479. [PMID: 30987380 PMCID: PMC6520695 DOI: 10.3390/cancers11040479] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Revised: 03/29/2019] [Accepted: 03/29/2019] [Indexed: 01/21/2023] Open
Abstract
A majority of breast cancer specific deaths in women with ERα (+) tumors occur due to metastases that are resistant to endocrine therapy. There is a critical need for novel therapeutic approaches to resensitize recurrent ERα (+) tumors to endocrine therapies. The objective of this study was to elucidate mechanisms of improved effectiveness of combined targeting of ERα and the nuclear transport protein XPO1 in overcoming endocrine resistance. Selinexor (SEL), an XPO1 antagonist, has been evaluated in multiple late stage clinical trials in patients with relapsed and /or refractory hematological and solid tumor malignancies. Our transcriptomics analysis showed that 4-Hydroxytamoxifen (4-OHT), SEL alone or their combination induced differential Akt signaling- and metabolism-associated gene expression profiles. Western blot analysis in endocrine resistant cell lines and xenograft models validated differential Akt phosphorylation. Using the Seahorse metabolic profiler, we showed that ERα-XPO1 targeting changed the metabolic phenotype of TAM-resistant breast cancer cells from an energetic to a quiescent profile. This finding demonstrated that combined targeting of XPO1 and ERα rewired the metabolic pathways and shut down both glycolytic and mitochondrial pathways that would eventually lead to autophagy. Remodeling metabolic pathways to regenerate new vulnerabilities in endocrine resistant breast tumors is novel, and given the need for better strategies to improve therapy response in relapsed ERα (+) tumors, our findings show great promise for uncovering the role that ERα-XPO1 crosstalk plays in reducing cancer recurrences.
Collapse
|